(3,5-二氟吡啶-2-基)甲胺二盐酸盐 | 1204298-48-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: (3,5-二氟吡啶-2-基)甲胺二盐酸盐
• 英文名称: (3,5-Difluoropyridin-2-yl)methanamine dihydrochloride
• 英文别名: (3,5-difluoropyridin-2-yl)methanamine;dihydrochloride
• CAS: 1204298-48-5
• 化学式: C6H8Cl2F2N2
• 分子量: 217.04
• InChiKey: PSLBYBLVOWTECG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.66
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  38.9
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

制备方法与用途

用途

2-(氨基甲基)-3,5-二氟吡啶二盐酸盐是2-(氨基甲基)-3,5-二氟吡啶的盐酸盐，用作医药中间体。

制备

将3,5-二氟吡啶甲腈（23.19 mmol）溶解在乙醇中，并加入浓盐酸水溶液（2.6 mL）。在氮气氛围下，加入10%钯/碳催化剂，然后使用帕尔设备以30 psi压力氢化2小时。通过过滤去除催化剂，并在减压下浓缩滤液。将残留物用乙酸乙酯（40 mL）和水（40 mL）萃取分离。用水溶液（3-4 mL 50% NaOH）调节pH至9，再用二氯甲烷（3×40 mL）萃取合并的有机层。干燥合并的萃取物后在减压下浓缩，得到浅绿色/棕色油状物（2.5 g，75%）。1H NMR (400 MHz, DMSO)显示：8.45 (1H, d)，7.89-7.84 (1H, m)，3.82 (2H, s)，3.33 (1H, bs)，1.87 (1H, bs)。

文献信息

• Ferroportin inhibitors
  申请人：Vifor (International) AG

  公开号：US10364239B2

  公开（公告）日：2019-07-30

  The invention relates to novel compounds of the general formula (A-I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula (AA) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.

  本发明涉及通式(A-I)的新型化合物，其中Het-2为通式(AA)的任选取代的双环杂芳基。本发明涉及由这些化合物组成的药物组合物及其作为药物的用途，特别是作为铁皮质素抑制剂的用途，尤其是用于预防和/或治疗由缺乏铁皮质素或铁代谢紊乱引起的疾病，如特别是铁过载状态，如地中海贫血症和血色病。
• FERROPORTIN INHIBITORS
  申请人：Vifor (International) AG

  公开号：EP3364967A2

  公开（公告）日：2018-08-29
• NOVEL FERROPORTIN INHIBITORS
  申请人：Vifor (International) AG

  公开号：EP3365339A1

  公开（公告）日：2018-08-29
• Novel Ferroportin Inhibitors
  申请人：Vifor (International) AG

  公开号：US20180297991A1

  公开（公告）日：2018-10-18

  The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
• [EN] NOVEL FERROPORTIN INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE LA FERROPORTINE
  申请人：VIFOR (INTERNATIONAL) AG

  公开号：WO2017068089A2

  公开（公告）日：2017-04-27

  The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.